Results 11 to 20 of about 1,688,023 (339)

Biomarkers [PDF]

Wiener Medizinische Wochenschrift, 2012
Biomarkers are characteristics objectively measured and evaluated as indicators of: normal biologic processes, pathogenic processes, or pharmacologic response(s) to a therapeutic intervention. In environmental research and risk assessment, biomarkers are frequently referred to as indicators of human or environmental hazards.
Harmony, Larson, Elena, Chan, Sucha, Sudarsanam, Dale E, Johnson   +3 more
  +7 more sources

Imaging Biomarkers or Biomarker Imaging? [PDF]

Pharmaceuticals, 2014
Since biomarker imaging is traditionally understood as imaging of molecular probes, we highly recommend to avoid any confusion with the previously defined term “imaging biomarkers” and, therefore, only use “molecular probe imaging (MPI)” in that context. Molecular probes (MPs) comprise all kinds of molecules administered to an organism which inherently
Markus Mitterhauser, Wolfgang Wadsak
openaire   +3 more sources

Biomarker Jeopardy

Journal of the Advanced Practitioner in Oncology, 2022
In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and discussed guidelines for biomarker ...
Kurtin, Sandra E., Henglefelt, Alyssa, Mistry, Haleigh   +2 more
openaire   +2 more sources

Epilepsy biomarkers [PDF]

Epilepsia, 2013
SummaryA biomarker is defined as an objectively measured characteristic of a normal or pathologic biologic process. Identification and proper validation of biomarkers of epileptogenesis (the development of epilepsy) and ictogenesis (the propensity to generate spontaneous seizures) might predict the development of an epilepsy condition; identify the ...
Pitkänen, Asla, Loeb, Jeffrey, Dudek, F, Bertram, Edward, Cole, Andrew, Moshé, Solomon, Wiebe, Samuel, Jensen, Frances, Mody, Istvan, Nehlig, Astrid, Vezzani, Annamaria, Engel, Jerome   +11 more
openaire   +5 more sources

Biomarker Jeopardy

Journal of the Advanced Practitioner in Oncology, 2021
The popular Biomarker Jeopardy session returned this year at JADPRO Live 2020. Sandra E. Kurtin, PhD, ANP-C, AOCN®, led the session, and was joined by Alyssa Henglefelt, PharmD, BCOP, and Allyson Price, PA-C. Using a Jeopardy format, they identified specific biomarkers while discussing targeted therapies and class effects APs should be aware of.
Kurtin, Sandra E., Henglefelt, Alyssa, Price, Allyson   +2 more
openaire   +3 more sources

Disease Knowledge Transfer across Neurodegenerative Diseases [PDF]

, 2019
We introduce Disease Knowledge Transfer (DKT), a novel technique for transferring biomarker information between related neurodegenerative diseases. DKT infers robust multimodal biomarker trajectories in rare neurodegenerative diseases even when only ...
Alexander, Daniel C., Blumberg, Stefano B., Crutch, Sebastian J., Eshaghi, Arman, Golland, Polina, Lorenzi, Marco, Marinescu, Razvan V., Morell, Pere P., Oxtoby, Neil P., Yong, Keir X., Young, Alexandra L.   +10 more
core   +4 more sources

Quality assessment and interference detection in targeted mass spectrometry data using machine learning

Clinical Proteomics, 2018
Advances in the field of targeted proteomics and mass spectrometry have significantly improved assay sensitivity and multiplexing capacity. The high-throughput nature of targeted proteomics experiments has increased the rate of data production, which ...
Shadi Toghi Eshghi, Paul Auger, W. Rodney Mathews   +2 more
doaj   +1 more source

A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling [PDF]

, 2019
It is well known that the treatment effect of a molecularly targeted agent (MTA) may vary dramatically, depending on each patient's biomarker profile. Therefore, for a clinical trial evaluating MTA, it is more reasonable to evaluate its treatment effect ...
Cao, Sha, Guo, Beibei, Han, Yan, Zang, Yong, Zhang, Chi   +4 more
core   +3 more sources

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]

, 2017
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger, Alcalay, Roy N., Babcock, Debra, Bowman, F. DuBois, Chen-Plotkin, Alice, David, Karen K., Dawson, Ted M., Dewey, Richard B., Jr., Foroud, Tatiana, German, Dwight, Gwinn, Katrina, Huang, Xuemei, Lungu, Codrin, Petyuk, Vlad, Potashkin, Judith A., Rosenthal, Liana S., Saunders-Pullman, Rachel, Scherzer, Clemens R., Sieber, Beth-Anne, St Hillaire-Clarke, Coryse, Sutherland, Margaret, Swanson-Fischer, Christine, Vaillancourt, David E., Walt, David R., West, Andrew B., Zhang, Jing   +25 more
core   +1 more source

Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials

Clinical and Translational Medicine, 2014
Background Clinically useful biomarkers for patient stratification and monitoring of disease progression and drug response are in big demand in drug development and for addressing potential safety concerns.
Martin Letzkus, Evert Luesink, Sandrine Starck‐Schwertz, Marc Bigaud, Fareed Mirza, Nicole Hartmann, Bernhard Gerstmayer, Uwe Janssen, Andreas Scherer, Martin M Schumacher, Aurelie Verles, Alessandra Vitaliti, Nanguneri Nirmala, Keith J Johnson, Frank Staedtler   +14 more
doaj   +1 more source